Cargando…
What Is New in the Treatment of Smoldering Multiple Myeloma?
Smoldering multiple myeloma (SMM), an asymptomatic plasma cell neoplasm, is currently diagnosed according to the updated IMWG criteria, which reflect an intermediate tumor mass between monoclonal gammopathy of undetermined significance (MGUS) and active MM. However, SMM is a heterogeneous entity and...
Autores principales: | Bolli, Niccolo’, Sgherza, Nicola, Curci, Paola, Rizzi, Rita, Strafella, Vanda, Delia, Mario, Gagliardi, Vito Pier, Neri, Antonino, Baldini, Luca, Albano, Francesco, Musto, Pellegrino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865294/ https://www.ncbi.nlm.nih.gov/pubmed/33499196 http://dx.doi.org/10.3390/jcm10030421 |
Ejemplares similares
-
Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021) -
Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021) -
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021) -
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020) -
P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma
por: Sgherza, Nicola, et al.
Publicado: (2022)